Global Rheumatoid Arthritis Therapeutics Market (By Type - Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region – North America, Europe & Asia Pacific) Market Outlook 2025
Clinical diagnoses of rheumatoid arthritis has seen a turnaround with advent of multiple antibody assays such as antibodies to citrullinated protein/peptide antigens (ACPAs). This helps in better diagnosis and management of RA with much improved overall diagnostic sensitivity. The market is also witnessing a shift towards combination therapy which manifests results.
The report “Global Rheumatoid Arthritis Therapeutics Market (By Type - Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region – North America, Europe & Asia Pacific) Market Outlook 2025” provides an in-depth analysis of global rheumatoid arthritis therapeutics market across therapeutics segments such as Pharmaceuticals and Biopharmaceuticals. Market outlook for rheumatoid arthritis therapeutics market overall as well as across various sub-segments has been provided for the period 2018-24. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global rheumatoid arthritis therapeutics market. The report has been segmented as following:-
Market Segments
The report “Global Rheumatoid Arthritis Therapeutics Market (By Type - Biologics, Biosimilars, NSAIDs, Analgesics, DMARDs & Glucocorticoids; By Region – North America, Europe & Asia Pacific) Market Outlook 2025” provides an in-depth analysis of global rheumatoid arthritis therapeutics market across therapeutics segments such as Pharmaceuticals and Biopharmaceuticals. Market outlook for rheumatoid arthritis therapeutics market overall as well as across various sub-segments has been provided for the period 2018-24. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global rheumatoid arthritis therapeutics market. The report has been segmented as following:-
Market Segments
- Pharmaceuticals
- NSAIDs
- DMARDs
- Analgesics
- Glucocorticoids
- Biopharmaceuticals
- Biologics
- Biosimilars
- North America - The US
- Europe
- Asia Pacific
- Abbvie Inc.
- Amgen Inc.
- F. Hoffman-La Roche AG
- Johnson & Johnson
- Pfizer Inc.
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
3. RHEUMATOID ARTHRITIS
3.1 Overview
3.2 Causes
3.3 Types of RA
4. RHEUMATOID ARTHRITIS DIAGNOSIS & TREATMENT
4.1 Diagnosis
4.2 Treatment
5. MARKET ANALYSIS
5.1 Market Sizing (Actual & Forecasted)
5.2 Market Share Analysis
5.2.1 Market Share by Molecule Type
5.2.2 Market Share by Distribution Channel
5.2.3 Market Share by Region
6. RHEUMATOID ARTHRITIS THERAPEUTICS
6.1 Biopharmaceuticals
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 Biologics
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Drug Type
6.1.3 Biosimilars
6.1.3.1 Market Sizing (Actual & Forecasted)
6.2 Pharmaceuticals
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 NSAIDs
6.2.3 Analgesics
6.2.4 DMARDs
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 Glucocorticoids
7. REGIONAL ANALYSIS
7.1 North America
7.1.1 Market Sizing (Actual & Forecasted)
7.1.2 Market Share by Molecule Type
7.2 Asia Pacific
7.2.1 Market Sizing (Actual & Forecasted)
7.3 Europe
7.3.1 Market Sizing (Actual & Forecasted)
8. MARKET DYNAMICS
8.1 Industry Trends & Developments
8.1.1 Preference for Combination Therapies
8.1.2 Growing Demand for Janus Kinase (JAK) inhibitors
8.1.3 Use of Anti-ACPAs for Clinical Diagnosis
8.1.4 FDA Approval of Auto-Injector for RA
8.2 Growth Drivers
8.2.1 Prevalence of Rheumatoid Arthritis
8.2.2 Increasing Geriatric Population
8.2.3 Growing Patient Awareness
8.3 Challenges
8.3.1 Entry of Biosimilars
8.3.2 High Cost of Treatment
8.3.3 Issues related to Insurance & Reimbursement
9. COMPETITIVE LANDSCAPE
10. COMPANY PROFILES
10.1 Abbvie Inc.
10.2 Amgen Inc.
10.3 F. Hoffmann-La Roche AG
10.4 Johnson & Johnson
10.5 Pfizer Inc.
2. RESEARCH METHODOLOGY
3. RHEUMATOID ARTHRITIS
3.1 Overview
3.2 Causes
3.3 Types of RA
4. RHEUMATOID ARTHRITIS DIAGNOSIS & TREATMENT
4.1 Diagnosis
4.2 Treatment
5. MARKET ANALYSIS
5.1 Market Sizing (Actual & Forecasted)
5.2 Market Share Analysis
5.2.1 Market Share by Molecule Type
5.2.2 Market Share by Distribution Channel
5.2.3 Market Share by Region
6. RHEUMATOID ARTHRITIS THERAPEUTICS
6.1 Biopharmaceuticals
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 Biologics
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Drug Type
6.1.3 Biosimilars
6.1.3.1 Market Sizing (Actual & Forecasted)
6.2 Pharmaceuticals
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 NSAIDs
6.2.3 Analgesics
6.2.4 DMARDs
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 Glucocorticoids
7. REGIONAL ANALYSIS
7.1 North America
7.1.1 Market Sizing (Actual & Forecasted)
7.1.2 Market Share by Molecule Type
7.2 Asia Pacific
7.2.1 Market Sizing (Actual & Forecasted)
7.3 Europe
7.3.1 Market Sizing (Actual & Forecasted)
8. MARKET DYNAMICS
8.1 Industry Trends & Developments
8.1.1 Preference for Combination Therapies
8.1.2 Growing Demand for Janus Kinase (JAK) inhibitors
8.1.3 Use of Anti-ACPAs for Clinical Diagnosis
8.1.4 FDA Approval of Auto-Injector for RA
8.2 Growth Drivers
8.2.1 Prevalence of Rheumatoid Arthritis
8.2.2 Increasing Geriatric Population
8.2.3 Growing Patient Awareness
8.3 Challenges
8.3.1 Entry of Biosimilars
8.3.2 High Cost of Treatment
8.3.3 Issues related to Insurance & Reimbursement
9. COMPETITIVE LANDSCAPE
10. COMPANY PROFILES
10.1 Abbvie Inc.
10.2 Amgen Inc.
10.3 F. Hoffmann-La Roche AG
10.4 Johnson & Johnson
10.5 Pfizer Inc.
